No discrete molecular target
Assets acting on this target.
- Class
- No single molecular target (whole-cell, viral, gene or multi-component therapy)
- Pathway
- innate-like γδ T-cell-mediated tumor cytotoxicity, primed by localized low-dose radiation
- Notes
- original target text: not a molecular receptor target -- allogeneic donor-derived cell product
This therapy is not built around a single molecular receptor or enzyme. Instead, it uses an entire immune cell type, gamma-delta (γδ) T cells, manufactured from a donor (allogeneic) rather than the patient, and delivered alongside localized low-dose radiotherapy to the tumor site. γδ T cells are a minority subset of T lymphocytes that recognize stressed or transformed cells through mechanisms that do not require matching the patient's own tissue markers (major histocompatibility complex, or MHC), unlike conventional T cells. This property makes them naturally suited to an 'off-the-shelf' allogeneic product, since they carry lower risk of attacking healthy host tissue or being rapidly rejected. Low-dose radiation is used not to directly kill the tumor but to alter it biologically: radiation-stressed tumor cells display more of the molecular flags that γδ T cells detect, and radiation can also loosen the local immunosuppressive environment that otherwise shields tumors from immune attack. Combining a donor-derived innate-like effector cell with a radiation 'priming' step is a strategy relevant across solid tumor types where immune cells struggle to recognize and penetrate tumor tissue. The general rationale extends to broader efforts in cellular immuno-oncology and combination approaches pairing cell therapies with conventional oncologic modalities.
No discrete molecular target drugs compared
8 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Vusolimogene oderparepvec (Tudriqev)Tudriqev | Replimune, Inc. | oncolytic virus | Approved | Approved in Melanoma; Phase 2 in Non-Small Cell Lung Cancer |
| Olvimulogene nanivacirepvec | Genelux Corporation, Newsoara HYK Biopharmaceuticals Co., Ltd. | oncolytic virus | Phase 3 | Phase 3 in Ovarian Cancer; Phase 2 in Non-Small Cell Lung Cancer |
| LN-145 | Iovance Biotherapeutics | cell therapy | Phase 2 | Phase 2 in Non-Small Cell Lung Cancer |
| Adipose-derived MSC clusters (S.Biomedics) | S.Biomedics | cell therapy (allogeneic adipose-derived MSC) | Phase 1/2 | Phase 1/2 in Atherosclerotic Cardiovascular Disease |
| BGC101 | BioGenCell | cell therapy (autologous endothelial progenitor cells) | Phase 1/2 | Phase 1/2 in Atherosclerotic Cardiovascular Disease |
| SL-28 | Second Life Therapeutics | cell therapy | Phase 1/2 | Phase 1/2 in Non-Small Cell Lung Cancer |
| ALF202 | Allife Medical Science and Technology | cell therapy (iPSC-derived endothelial progenitor cells) | Phase 1 | Phase 1 in Atherosclerotic Cardiovascular Disease |
| KB-GDT-01 | Immunocell Therapeutics, Inc. | cell therapy | Phase 1 | Phase 1 in Non-Small Cell Lung Cancer |